Quest Diagnostics Incorporated (DGX) Earnings Call Transcripts

Quest Diagnostics Incorporated's Latest Earnings Call - Q2 FY2026

In the second quarter of 2026, Quest Diagnostics reported revenues of $3.04 billion, reflecting a robust growth of 10.2% year-over-year, primarily driven by strong clinical demand across various channels. Adjusted diluted earnings per share (EPS) increased by 19.1% to $3.12, surpassing expectations. Management raised full-year guidance, now projecting revenues between $11.95 billion and $12.05 billion, and adjusted EPS of $11.05 to $11.25, signaling confidence in sustained demand and operational efficiency improvements.

Reported metrics

Guidance from management

Management raised full-year revenue guidance to between $11.95 billion and $12.05 billion, and adjusted EPS guidance to a range of $11.05 to $11.25, reflecting confidence in sustained demand and operational improvements.

What management said

So Lisa, just to reaffirm what Jim said in terms of our guidance for the year, we're still assuming for the full year that there's a 30 basis point impact on revenue from the ACA exchange subsidy expiration.

The other thing you didn't ask, but it came up in the prior question. Look, the Fresenius book of business is a significant revenue increase year-over-year as well, close to $100 million. And the margin profile of that business continues to improve from Q1 to Q2 to Q3 and into Q4. So that is also giving us lift from an operating margin perspective in the second half of the year.

What analysts pressed on

Analysts expressed concerns regarding potential headwinds from ACA changes impacting revenue, particularly a 30 basis point expected impact. Additionally, there were questions about pricing pressures and bad debt trends in the hospital sector, given broader industry challenges.

Main topics on the call

• Revenue Growth — Quest Diagnostics achieved a revenue growth of 10.2% year-over-year, driven by strong demand across physician, hospital, and consumer channels. Management noted, "We grew revenues by over 10%, driven by broad clinical de...
• Earnings Performance — Adjusted diluted EPS increased by 19.1% to $3.12, largely due to strong organic revenue growth and a favorable resolution of tax contingencies. Management highlighted that the improvement was primarily driven by "strong ...
• Guidance Update — Management raised full-year guidance, now expecting revenues between $11.95 billion and $12.05 billion, reflecting a growth rate of 8.3% to 9.2%. They stated, "We are again raising our guidance for the year," indicating ...
• Operational Efficiency — The company is on track to deliver 3% in annual cost savings and productivity improvements through its Invigorate program. Management emphasized, "We are also using advanced technologies to make it easier for our custome...

Read the full Quest Diagnostics Incorporated transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 68 Quest Diagnostics Incorporated earnings call transcripts on record, spanning January 15, 2020 to July 23, 2026. Based on this history, Quest Diagnostics Incorporated reports quarterly. The most recent call on file is dated July 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DGX

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

68

First call

January 15, 2020

Most recent

July 23, 2026

Reporting cadence

quarterly